×
ProPhase Labs EBIT 2010-2025 | PRPH
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
ProPhase Labs ebit from 2010 to 2025. Ebit can be defined as earnings before interest and taxes.
View More
ProPhase Labs EBIT 2010-2025 | PRPH
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
ProPhase Labs ebit from 2010 to 2025. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$76.8B
Zoetis (ZTS)
$66.8B
Takeda Pharmaceutical (TAK)
$46.9B
Daiichi Sankyo, - (DSNKY)
$45.5B
BeOne Medicines - (ONC)
$31.8B
Sandoz Group AG (SDZNY)
$24.6B
Summit Therapeutics (SMMT)
$20.5B
Merck (MKKGY)
$16.7B
Shionogi (SGIOY)
$14.4B
United Therapeutics (UTHR)
$13.4B
Neurocrine Biosciences (NBIX)
$13.3B
Orion OYJ (ORINY)
$11B
IPSEN (IPSEY)
$10.5B
Corcept Therapeutics (CORT)
$7.8B
Madrigal Pharmaceuticals (MDGL)
$7.7B
Stevanato Group S.p.A (STVN)
$7.7B
Grifols, S.A (GRFS)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.7B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.4B
Crinetics Pharmaceuticals (CRNX)
$3.1B
Hypermarcas (HYPMY)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
NewAmsterdam Pharma (NAMS)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.1B
BioCryst Pharmaceuticals (BCRX)
$1.8B
Ocular Therapeutix (OCUL)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.8B